Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
about
Use of metformin in diseases of aging[Obesity in old age and its importance for functionality and frailty].The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data.Leptin resistance after heart transplantation.The link of unintentional weight loss to cardiac event-free survival in patients with heart failureAngiotensin II infusion induces marked diaphragmatic skeletal muscle atrophyAtomoxetine prevents dexamethasone-induced skeletal muscle atrophy in miceBody mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trialWeight and mortality following heart failure hospitalization among diabetic patients.Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexiaNutritional Risk Index predicts mortality in hospitalized advanced heart failure patientsAcylation of ghrelin is increased in heart failure and decreases post heart transplantation.Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure.Effect of Obesity and Underweight Status on Perioperative Outcomes of Congenital Heart Operations in Children, Adolescents, and Young Adults: An Analysis of Data from the Society of Thoracic Surgeons Database.Weight Loss in Obese Patients With Heart Failure.Adjusting for reverse causation to estimate the effect of obesity on mortality after incident heart failure in the Atherosclerosis Risk in Communities (ARIC) studyGrowth hormone resistance in severe heart failure resolves after cardiac transplantation.Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation.Role of carvedilol controlled-release in cardiovascular disease.Glucose and insulin abnormalities in patients with heart failure.The obesity paradox in heart failure: accepting reality and making rational decisions.Multivariate risk scores and patient outcomes in advanced heart failure.Obesity in heart failure: impact on survival and treatment modalities.The obesity paradox in chronic heart failure: what does it mean?Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure?Healthy obese versus unhealthy lean: the obesity paradox.The paradox of obesity cardiomyopathy and the potential for weight loss as a therapy.Management of Noncardiac Comorbidities in Chronic Heart Failure.Epidemiology of Multimorbidity in Older Adults with Cardiovascular Disease.The interplay between heart failure, metabolism and body composition.Effect of Significant Weight Change on Inappropriate Implantable Cardioverter-Defibrillator Therapy.[Better chance of survival for the overweight and elderly].Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials.Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status.Perils of weight loss: the advantage of being obese in patients with heart failure.miR-424-5p reduces ribosomal RNA and protein synthesis in muscle wasting.Presence of obesity is associated with lower mortality in elderly patients with implantable cardioverter defibrillator.High nutritional risk is associated with worse health-related quality of life in patients with heart failure beyond sodium intake.Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure.Effects of cyanidin 3-0-glucoside on cardiac structure and function in an animal model of myocardial infarction.
P2860
Q26828760-F0AE1606-FE47-4AA3-B32B-B8559B4915CAQ30245310-7667443D-B51C-4E59-AFF1-2858A59F44BFQ30686199-29428C77-B9B7-45F0-B6D8-FF9FF0879BC2Q33803821-EB7386F1-5033-4E49-8C6A-DA34646DB021Q34036472-4184BA90-0D6B-4821-B0C0-EC040EB3C8CEQ34140453-91887365-B30E-4768-AFD4-8FE1EF23910CQ34573906-485A4091-EB7A-49D5-A2F8-88B093D5E203Q34999484-FA586D7C-6F5A-4330-AE26-9AF12944D445Q35178168-8FC31B6B-DF3D-4001-8000-53B58DC024BEQ35569439-B7AD605B-A317-4F7B-AECF-9259F4BC5225Q36202751-2E18AFFE-0BE6-4268-BC8E-AC4DBF5C2B79Q36277093-6061600C-218B-4885-8360-8E6C6892F56AQ36349354-73561B30-7B80-42B6-B6C3-B5A7CF8116ADQ36408544-ED90A354-7FBE-4761-9472-A4BB1D2F2A64Q37090681-4EF3DDFA-4516-49DF-AADC-A8860248DB9AQ37153561-3AD7DD2B-C6CD-4A88-A102-62282A003A15Q37166186-887D41D7-AB4B-4399-930F-3D9F4950107DQ37273594-0618E960-732B-4725-B890-D177485D1D12Q37472042-9B35F3B0-6D7F-4748-A537-7FE4CA2C098DQ37801130-EABF8AAD-149C-4A98-A37F-46EF417D5BDCQ37886663-9D9AB778-84D1-4B1F-841B-FDBAC5346CC6Q37929862-990EE948-D3F9-4697-BE66-C179B95C0802Q38128922-09B91DB0-99F9-4CBF-B698-31F2C0B794A9Q38180334-12AD7F01-B370-4BCB-A5A5-2D2AA001DE8DQ38189707-8C53E328-95DD-432A-B07D-FA8E9A9025B3Q38255271-8543CE95-D2AC-45BC-9278-E23EFBFC1B7AQ38533878-C3058E61-3B7E-4B49-BA16-B8943BE22F55Q38537053-8EC4ED85-B71A-485C-991D-9D161FBE43A4Q38817285-716429A6-749A-4754-9BB5-A889CAA50EE3Q38857371-66F54092-9B39-4A77-977B-BCDFE994AE2FQ39221183-3FCEDE94-44FB-423D-A689-83E195E6F323Q44292442-749130FE-8DBC-4ECF-8AC7-944AAB9A1837Q44964814-122C3BCC-EDD5-454F-9524-8F0E63CEB6AEQ45150879-BD783B2A-06D3-4FB6-A7FC-5619717F59DCQ46083549-885FBB33-321F-4627-B283-9E3497A562F3Q47320378-85D7C9A2-E3EF-4BED-B0D4-4950CCCA1477Q47805529-EE319804-7B95-4B4F-AFBF-A45E9E3763E9Q48434731-CBBA9195-F449-4246-AE9D-F53B46AB90DDQ48680998-772432F0-B7D4-480C-AE44-B680B97FE46BQ49485518-7BD0E4C9-4F76-4953-B5B9-8944FCA7D0CE
P2860
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Weight loss and mortality risk ...... d morbidity (CHARM) programme.
@en
Weight loss and mortality risk ...... ion in mortality and morbidity
@nl
type
label
Weight loss and mortality risk ...... d morbidity (CHARM) programme.
@en
Weight loss and mortality risk ...... ion in mortality and morbidity
@nl
prefLabel
Weight loss and mortality risk ...... d morbidity (CHARM) programme.
@en
Weight loss and mortality risk ...... ion in mortality and morbidity
@nl
P2093
P2860
P50
P356
P1476
Weight loss and mortality risk ...... d morbidity (CHARM) programme.
@en
P2093
Eric L Michelson
Jan Ostergren
Joanna Dobson
John J V McMurray
Karl B Swedberg
Marc A Pfeffer
Scott D Solomon
Stuart J Pocock
P2860
P304
P356
10.1093/EURHEARTJ/EHN420
P577
2008-09-26T00:00:00Z